POETYK II Trial
Right now, Bristol Myers Squibb is doing research to see if deucravacitinib, an investigational pill for systemic lupus erythematosus, or SLE for short, can improve disease activity and symptoms in people with SLE.
Deucravacitinib is a pill that has already been studied and approved for moderate to severe plaque psoriasis in multiple countries based on two large phase 3 studies of 1,681 people.
Screening Process
Before you can join the study, you will need to take part in the screening period, during which tests and health checks will be done to see if you meet the requirements for joining. If you meet requirements, you may enter the study and be randomized into a treatment arm.
Eligible participants must:
- Be 18 to 75 years of age
- Have a diagnosis of active SLE with signs and symptoms including joint involvement, cutaneous vasculitis, and/or rash
- Have positive antibodies (ANA, or anti-dsDNA or anti-Smith) based on laboratory screening
- Be receiving a background therapy for SLE
- NOT be diagnosed with other autoimmune diseases (for example, multiple sclerosis, psoriasis, inflammatory bowel disease, etc.)
- Exceptions: type 1 diabetes mellitus, thyroid autoimmune disease, celiac disease, and secondary Sjögren’s syndrome
There are additional requirements for joining the study that the study doctor can explain to you.